The researchers found that Paxlovid reduced hospitalizations among people 65 and older by roughly 75% when given shortly after infection:
. For younger adults, in particular, that greatly reduces their risks of severe COVID-19 complications. The Centers for Disease Control and Prevention recently estimated that 95% of Americans 16 and older have acquired some level of immunity against the virus.
A spokesman for Pfizer declined to comment on the results, which were published in the New England Journal of Medicine.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer’s COVID-19 pill appears to provide little or no benefit for younger adults.
Weiterlesen »
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Weiterlesen »
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Weiterlesen »
Paxlovid, Pfizer's COVID pill, showed no measurable benefit in adults 40 to 65, study saysPfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Weiterlesen »
COVID Antivirals Like Paxlovid ‘Vastly Underused' During Pandemic, Study SaysDespite clinical trials showing that it could significantly reduce the risk of death in COVID patients, studies have shown that antivirals like Paxlovid are being “vastly underused” during the pandemic.
Weiterlesen »